Giulia KennedyPhD
Chest · 2024

A Nasal Swab Classifier to Evaluate the Probability of Lung Cancer in Patients With Pulmonary Nodules

Lamb CR, Rieger-Christ KM, Reddy C, Huang J, Ding J, Johnson M, Walsh PS, Bulman WA, Lofaro LR, Wahidi MM, Feller-Kopman DJ, Spira A, Kennedy GC, Mazzone PJ

Co-authorstrongly supportedPulmonary genomic classifiersMachine learning for clinical diagnostics
Journal
Chest · vol. 165 · no. 4 · pp. 1009-1019
Published
Apr 2024

Synopsis

Validation of the Percepta Nasal Swab clinical-genomic classifier for lung cancer risk in patients with pulmonary nodules. In the primary validation set, sensitivity and specificity for low-risk classification were 96% and 42%, and for high-risk classification 58% and 90%. Kennedy is thirteenth of fourteen authors; Veracyte had announced the pivotal validation data on May 19, 2021, and the paper appeared after her December 2022 departure.

In the career genome

  • VeracyteChapter 06 · Strand A · Company
    Veracyte, Inc.

    Veracyte

    Chief Scientific Officer; Chief Medical Officer from 2018; Global Chief Scientific Officer and Chief Medical Officer from 2022

    APR 2008 – DEC 2022
  • VeracyteChapter 09 · Strand B · Research
    Veracyte, Inc.

    Percepta and Envisia

    Chief Scientific Officer and Chief Medical Officer, Veracyte

    APR 2015 – APR 2024